USTEKINUMAB: A GENETICALLY ENGINEERED BIOLOGIC FOR PSORIASIS TREATMENT – A CASE REPORT
Introduction: One of the critical challenges in modern dermatology is ensuring the effectiveness of treatment for patients with moderate-to-severe psoriasis. The introduction of genetically engineered biological therapies targeting specific pro-inflammatory cytokines has significantly advanced the management of this condition and improved patients' quality of life.
The aim of the study is to evaluate the clinical effectiveness of ustekinumab in a patient with severe psoriasis.
Materials and Methods: A retrospective case analysis was conducted using the medical records of a single patient who received inpatient treatment at the dermatovenereology department of City Hospital № 2, under the Abay Regional Health Authority. The patient's condition was monitored through the Comprehensive Medical Information System (CMIS) during the period from 2011 to 2024. Diagnostic and therapeutic procedures were performed in accordance with the approved clinical protocol of the Ministry of Health of the Republic of Kazakhstan № 172, dated October 14, 2022. The publication of treatment outcomes was authorized by the hospital administration and the patient through signed informed consent.
Results: After the addition of Stelara to standard anti-inflammatory therapy, the patient’s condition improved significantly. The drug alleviated symptoms such as skin itching, rashes, and joint pain. Clinical studies have demonstrated that ustekinumab effectively controls disease progression and enhances patients’ quality of life by reducing pro-inflammatory cytokines and modulating anti-inflammatory markers. Research has also confirmed its efficacy in treating psoriatic arthritis symptoms and its success across diverse populations, with 67.2% of patients achieving PASI75 after two doses.
Conclusion: This clinical case demonstrates the effectiveness of ustekinumab in treating moderate-to-severe psoriasis complicated by psoriatic arthritis. The improvement in skin lesions, joint symptoms, and overall patient condition highlights the potential of biological therapy in disease management and enhancing quality of life.
Akhmetova Almira Kalikapasovna - Candidate of Medical Sciences, Acting Professor of the Department of Infectious Diseases, Dermatovenerology and Immunology, NJSC "Semey Medical University", phone: 8 701 388 13 37, e-mail: almirahmetova@mail.ru, https://orcid.org/0000-0002-8938-3401, Semey, Kazakhstan;
Dyusseneva Dinara Kenesovna - Dermatovenerologist at City Hospital № 2, phone: 8 707 695 43 74, e-mail: dermatolog19@mail.ru, Semey, Kazakhstan;
Kussainova Assiya Abikhasovna - PhD, Acting Associate Professor Department of General practice with a course of evidence-based medicine, NJSC "Astana Medical University", phone: 8 707 498 73 48, e-mail: kuzilas@mail.ru, https://orcid.org/0000 0002-5738-0804, Astana, Kazakhstan;
Seidullaeva Aliya Zhaldybaevna - PhD, Associate Professor, Department of Pediatric Infectious Diseases, NJSC "Astana Medical University", e-mail: seidullayeva.aliya@gmail.com, https://orcid.org/0000-0002-7513-5677, Astana, Kazakhstan,
Kozhakhmetova Dana Kenzhibaevna - аssistant of the Department of Internal Medicine and Rheumatology, NJSC "Semey Medical University", phone: 8 702 705 14 03, e-mail: dana.kozhakhmetova@smu.edu.kz, https://orcid.org/0000 0002-8367-1461, Semey, Kazakhstan;
Botabayeva Ainur Serikzhanovna - аssistant of the Department of Internal Medicine and Rheumatology, NJSC "Semey Medical University", phone: 8 701 100 20 98, e-mail: ainur.botabayeva@smu.edu.kz, Semey, Republic of Kazakhstan;
Shamshudinov Timur Maratovich – PhD, «Medical and diagnostic Center of otorhinolaryngology» PRO-LOR, phone: 8 701 204 10 70, e-mail: dr.shamshudinov@mail.ru, https://orcid.org/0000-0001-5015-871X, Almaty, Kazakhstan;
Zhokebaeva Madiana Seytkazovna - аssistant of the Department of Infectious Diseases, Dermatovenerology and Immunology, NJSC "Semey Medical University", phone: 8 775 038 19 14, e-mail: zhokebaeva@inbox.ru, Semey, Kazakhstan;
Petrova Yuliya Viktorovna - аssistant of the Department of Internal Medicine and Rheumatology, NJSC "Semey Medical University", phone: 8 771 537 60 60, e-mail: Shahvorostova_yu@mail.ru, Semey, Kazakhstan;
Kassym Laura Talgatkyzy – PhD, Associate Professor Department of General practice with a course of evidence-based medicine, NJSC "Astana Medical University", phone: 8 777 735 10 62, е-mail: laura.kassym@gmail.com, https://orcid.org/0000-0003-4448-6455, Astana, Kazakhstan.
1. Цечеева Ф.Б. Генно-инженерные биологические препараты в дерматологии (обзор литературы). Вопросы дерматологии и венерологии. 2020. №3-3. 7-17
2. Brandon A., Mufti A., Gary Sibbald R. Diagnosis and Management of Cutaneous Psoriasis: A Review. Adv Skin Wound Care. 2019. 32(2). 58-69. doi: 10.1097/01.ASW.0000550592.08674.43.
3. Dobbin-Sears I., Roberts J., O'Rielly D.D., Rahman P. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis. 2018. 9(10). 191-198.
4. Gordon K.B., Strober B., Lebwohl M., Augustin M., Blauvelt A., Poulin Y., Papp K.A., et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018. 392(10148). 650-661.
5. Gottlieb A., Menter A., Mendelsohn A. et al. Ustekinumab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009. 373. 633–40.
6. Gottlieb A.B., Cooper K.D., McCormick T.S. et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007. 23. 1081–92.
7. Griffiths C.E.M., Strober B.E., van de Kerkhof P. et al. ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010. 362. 118–28.
8. Griffiths C.E., Armstrong A.W., Gudjonsson J.E., Barker J.N. Psoriasis. Lancet. 2021. 397(10281). 1301-1315. doi: 10.1016/S0140-6736(20)32549-6.
9. Gross G., Lull C., von Ahnen J.A., Blauth M., Schwaan J., Olsavszky V., Schmieder A., Leipe J. Interdisciplinary approach to patients with psoriatic arthritis: a prospective, single-center cohort study. Ther Adv Chronic Dis. 2024. 15. 20406223241293698. doi: 10.1177/20406223241293698.
10. Igarashi A., Kato T., Kato M., et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012. 39. 242–252.
11. Kauffman C.L., Aria N., Toichi E. et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004. 123. 1037–44.
12. Kim E., Fischer G. Relationship between PASI and FDLQI in paediatric psoriasis, and treatments used in daily clinical practice. Australas J Dermatol. 2021. 62(2). 190-194. doi: 10.1111/ajd.13536.
13. Krueger G.G., Langley R.G., Leonardi C. et al. A human inter leukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007. 356. 580–92.
14. Leonardi C.L., Kimball A.B., Papp K.A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008. 371. 1665–74.
15. Papp K.A., Langley R.G., Lebwohl M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008. 371. 1675–84.
16. Parisi R., Iskandar IYK., Kontopantelis E., Augustin M., Griffiths CEM., Ashcroft DM. Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020. 369. m1590. doi: 10.1136/bmj.m1590.
17. Petit R.G., Cano A., Ortiz A., Espina M., Prat J., Muñoz M., Severino P., Souto E.B., García M.L., Pujol M., Sánchez-López E. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci. 2021. 22(9). 4983. doi: 10.3390/ijms22094983.
18. Ritchlin C., Rahman P., Kavanaugh A., McInnes I. B., Puig L., Li S., Wang Y., Shen Y. K., Doyle M. K., Mendelsohn A. M., Gottlieb A.B., & PSUMMIT 2 Study Group Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the rheumatic diseases. 73(6). 990–999. https://doi.org/10.1136/annrheumdis-2013-204655
19. Sugumaran D., Yong A.C., Stanslas J. Advances in psoriasis research: From pathogenesis to therapeutics. Life Sci. 2024. 355. 122991. doi: 10.1016/j.lfs.2024.122991.
20. Svedbom A., Mallbris L., González-Cantero Á., Playford M., Wu C., Mehta N.N., Ståhle M. Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis. JAMA Dermatol. 2024. e244433. doi: 10.1001/jamadermatol.2024.4433
21. Tsai T.F., Ho J.C., Song M. et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011. 63. 154–163.
22. Weilin Z., Guoqiang Z., Xingxing R., Mingsong L. Research progress of Ustekinumab in the treatment of inflammatory bowel disease. Frontiers in Immunology. 2024. 15. 1322054.
23. Yegorov S., Babenko D., Kozhakhmetov S., Akhmaltdinova L., Kadyrova I., Nurgozhina A., Nurgaziyev M., Good S.V., Hortelano G.H., Yermekbayeva B., Kushugulova A. Psoriasis Is Associated With Elevated Gut IL-1α and Intestinal Microbiome Alterations. Front Immunol. 2020. 11. 571319. doi: 10.3389/fimmu.2020.571319.
24. Zhu X., Zheng M., Song M. et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaquetype psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013. 12. 166–174.
Number of Views: 48
Category of articles:
Clinical case
Bibliography link
Akhmetova A.K., Dyusseneva D.K., Kussainova A.A., Seidullaeva A.Zh., Kozhakhmetova D.K., Botabayeva A.S., Shamshudinov T.M., Zhokebaeva M.S., Petrova Yu.V., Kassym L.T. Ustekinumab: a genetically engineered biologic for Psoriasis treatment – a case report // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (6), pp. 211-218. doi 10.34689/SH.2024.26.6.023Related publications:
COMMUNITY-ACQUIRED PNEUMONIA IN PREGNANT. CLINICAL CASE.
A CASE OF AUTOIMMUNE COMPLICATIONS FOLLOWING COVID-19 VACCINATION WITH SINOVAC-CORONAVAC (CHINA)
EOSINOPHILIC GASTROINTESTINAL DISEASES IN CHILDREN. СLINICAL CASE.
USE OF A NEW DEVICE FOR DRAINAGE OF THE PLEURAL CAVITY IN CHILDREN
USTEKINUMAB: A GENETICALLY ENGINEERED BIOLOGIC FOR PSORIASIS TREATMENT – A CASE REPORT